Familial Hypercholesterolemia (FH) in Iran: Findings from the Four-Year FH Registry
Table 1
Baseline characteristics of subjects with familial hypercholesterolemia by Dutch Lipid Clinic Network diagnosis.
Possible ( (66.9%)
Probable ( (18.7%))
Definite ( (14.3%))
Definite and probable ( (33.1%))
Total ()
Demographics
Sex (male)
169 (48.4)
37 (37.8)
27 (36.0)
64 (37.0)
233 (44.6)
Age (years)
Family history of premature CVDa
72 (21.0)
51 (54.3)
26 (36.6)
77 (46.7)
149 (29.3)
Smoking status
Never
292 (83.4)
77 (78.6)
68 (90.7)
145 (83.8)
437 (83.6)
Current
42 (12)
15 (15.3)
3 (4)
18 (10.4)
60 (11.5)
Previous
16 (4.6)
6 (6.1)
4 (5.3)
10 (5.8)
26 (50.0)
Presence of Achilles tendon
0 (0)
1 (1.1)
13 (18.3)
14 (8.4)
14 (2.8)
Xanthomas
0 (0)
7 (7.3)
42 (56.8)
49 (28.8)
49 (9.6)
Arcus cornealis
0 (0)
6 (6.1)
1 (1.3)
7 (4.0)
7 (1.3)
Body mass index (kg/m2)
Comorbidities
Hypertension
82 (23.6)
38 (40.4)
20 (27.4)
58 (34.7)
140 (27.2)
Diabetes mellitus
56 (16.3)
20 (22.2)
14 (19.7)
34 (21.1)
90 (17.8)
History of CVD
33 (9.4)
46 (46.9)
17 (22.7)
63 (36.4)
96 (18.4)
Biochemical measures
Total cholesterol (mg/dl)
LDL-cholesterolb (mgr/dl)
HDL-cholesterol (mgr/dl)
Non-HDL cholesterol (mg/dl)
Triglycerides (mgr/dl)
FBSd
HbA1ce
History of pharmacotherapy
Lipid-lowering drugs
168 (48)
65 (66.3)
54 (72)
119 (68.8)
287 (54.9)
Antihypertensive
65 (18.6)
25 (25.5)
12 (16)
37 (21.4)
102 (19.5)
Antidiabetics
38 (10.9)
16 (16.3)
8 (10.7)
24 (13.9)
62 (11.9)
Aspirin
31 (8.9)
13 (13.3)
6 (8.0)
19 (11.0)
50 (9.6)
Data are shown as or frequency (percentage). aCVD: cardiovascular disease. bLDL-cholesterol: low-density lipoprotein cholesterol. cHDL-cholesterol: high-density lipoprotein cholesterol. dFBS: fast blood sugar. eHbA1c: hemoglobin A1c.
